Oligonucleotide Purification Patents: Leaders & White Space 2026
Oligonucleotide Purification and Analysis Patents: Who Holds the Ground
One assignee dominates the ranking. The leader sits at 15 records against a fifth-place count of 5 and a tenth-place count of 4 — a steep drop-off rather than a gradual one. Filings rose to a peak of 6 in 2019, then the tracked 2021-2024 window fell from 2 to 0 records, a -100% change. Because publication lags filing by roughly 18 months, the 2025-26 entries in the chart are still incomplete and should not be read as a continued decline on their own.
- 1WATERS TECHNOLOGY CORP15
- 2THIRD WAVE TECHNOLOGIES INC9
- 3BECTON DICKINSON & CO7
- 4WATERS TECH IRELAND LIMITED IE6
- 5RGT UNIV OF CALIFORNIA5
See the full oligonucleotide purification and analysis analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who are the leading patent holders in oligonucleotide purification and analysis?
The ranked field covers 33 companies, with the leading assignee holding 15 records compared with 5 at fifth place and 4 at tenth place. That drop-off means the field is not evenly split among several equal competitors; one organisation built a substantially larger portfolio in assay and detection methods than anyone else in this scope. A freedom-to-operate check should weight that leader’s claims more heavily than the rest of the ranked list.
Is filing activity in this space growing or shrinking?
The tracked window shows a fall from 2 records in 2021 to 0 in 2024, a -100% change, after a peak of 6 records in 2019. However, because patent publication typically lags filing by around 18 months, the 2025-26 figures in this dataset are still incomplete and should not be read as proof the field has gone cold. A cleaner read will only be available once those years finish publishing.
What does US20060160074A1 actually cover?
US20060160074A1, assigned to Third Wave Technologies and published 2006-07-20, covers methods for detecting polymorphisms in drug-metabolizing enzymes such as UGT and cytochrome p450 using non-amplified oligonucleotide detection assays, plus related kits. It is one of the most-cited records in this scope, with 67 citations, alongside a closely related sibling application also at 67. Anyone building a non-amplified detection assay for pharmacogenetic targets should review its claim scope directly rather than relying on citation count alone.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Oligonucleotide Purification and Analysis covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.